LTR Pharma Limited
LTPLF
$0.27
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -34.20% | -32.66% | -- | -- | -- |
| Gross Profit | 69.93% | 69.23% | -- | -- | -- |
| SG&A Expenses | 46.09% | 49.49% | 517.89% | 502.50% | 308.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 430.53% | 440.91% | 3,669.70% | 3,550.00% | 138.18% |
| Total Operating Expenses | 12.22% | 14.86% | 408.73% | 396.17% | 339.04% |
| Operating Income | 5.56% | 3.35% | -403.12% | -390.69% | -339.04% |
| Income Before Tax | 5.24% | 3.03% | -401.65% | -389.32% | -328.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.24% | 3.03% | -401.65% | -389.32% | -328.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.24% | 3.03% | -401.65% | -389.32% | -328.89% |
| EBIT | 5.56% | 3.35% | -403.12% | -390.69% | -339.04% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 13.56% | 11.67% | -1,385.71% | -1,385.71% | -227.78% |
| Normalized Basic EPS | 13.51% | 10.81% | -1,525.00% | -1,525.00% | -208.33% |
| EPS Diluted | 13.56% | 11.67% | -1,385.71% | -1,385.71% | -227.78% |
| Normalized Diluted EPS | 13.51% | 10.81% | -1,525.00% | -1,525.00% | -208.33% |
| Average Basic Shares Outstanding | 9.86% | 9.86% | -66.43% | -66.43% | 33.17% |
| Average Diluted Shares Outstanding | 9.86% | 9.86% | -66.43% | -66.43% | 33.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |